Adverse complications and graft survival
Rejection occurred in three patients, two in the A+P group and one in
the paxlovid group; death occurred in four patients, all in the
combination group; graft inactivation occurred in five patients, two in
the paxlovid group and three in the A+P group; new-onset urinary albumin
positivity occurred in seven patients, four in the azvudine group, two
in the paxlovid group and one in the A+P group; and acute kidney injury
occurred in 30 patients: 7 in the azvudine group, 17 in the Paxlovid
group, and 6 in the A+P group.
Kaplan–Meier survival curves were plotted for the risk of adverse
events in the three groups, using ICU admission or death as the
observation endpoint, with the lowest incidence of adverse events during
the observation period recorded in the azvudine group; however, the
difference in risk between the three groups was not statistically
significant (log-rank test, P=0.069).
Kaplan–Meier curves were also plotted for graft survival between the
three treatment groups, with no graft failure The best graft survival
was in the azvudine group, and the lowest graft survival in the A+P
group, with a statistical difference between the three groups (log-rank
test P=0.037).
In this study, the observed adverse outcomes were ICU admission or
death. To examine the differences in the occurrence of adverse outcomes
among the three treatment modalities in more detail, we used the
occurrence of adverse outcomes as the dependent variable; age, time
since kidney transplantation, treatment group, and pneumonia type were
the independent variables in a multifactorial logistic regression
equation. Differences in the occurrence of adverse outcomes among the
three treatment modalities were analyzed after adjusting for other
factors. Age (years) and time since transplantation (months) were
included in the equation as continuous variables, and the pneumonia
subtype (1 for severe or critical, 0 for other) and treatment regimen
were categorical variables. The results showed no significant
differences in the occurrence of adverse events among the three groups
after adjusting for other baseline values (Table 4).